WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017194632) IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/194632    International Application No.:    PCT/EP2017/061229
Publication Date: 16.11.2017 International Filing Date: 10.05.2017
IPC:
C07D 471/04 (2006.01), A61K 31/437 (2006.01), A61P 35/00 (2006.01)
Applicants: ASTRAZENECA AB [SE/SE]; SE-151 85 Södertälje (SE)
Inventors: BARLAAM, Bernard, Christophe; (GB).
PIKE, Kurt, Gordon; (GB)
Agent: NESS, Mark; (GB)
Priority Data:
1608227.3 11.05.2016 GB
Title (EN) IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER
(FR) COMPOSÉS IMIDAZO[4,5-C]QUINOLIN-2-ONE ET LEUR UTILISATION POUR TRAITER LE CANCER
Abstract: front page image
(EN)The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where R1 is 4-fluoropiperidin-1-yl or 3-fluoropyrrolidin-1-yl and R2 is methyl or hydro; the use of compounds of Formula (I) or pharmaceutically acceptable salts thereof to treat or prevent ATM mediated disease, including cancer; pharmaceutical compositions comprising substituted imidazo[4,5- c]quinolin-2-one compounds or pharmaceutically acceptable salts thereof; kits comprising compounds of Formula (I) or pharmaceutically acceptable salts thereof; methods of manufacture of compounds of Formula (I) or pharmaceutically acceptable salts thereof; and intermediates useful in such manufacture.
(FR)La présente invention concerne d'une manière générale des composés de formule (I) et des sels correspondants pharmaceutiquement acceptables, R1 étant du 4-fluoropipéridin-1-yle ou du 3-fluoropyrrolidin-1-yle; et R2 étant méthyle ou hydro; l'utilisation des composés de formule (I) ou de ses sels pharmaceutiquement acceptables pour traiter ou prévenir une maladie conditionnée par l'ATM (ataxie télangiectasie muté), y compris le cancer; des compositions pharmaceutiques comprenant des composés imidazo [4,5-c]quinolin-2-one substitués ou de ses sels pharmaceutiquement acceptables; des kits comprenant les composés de formule (I) ou ses sels pharmaceutiquement acceptables; des procédés de fabrication des composés de formule (I) ou de ses sels pharmaceutiquement acceptables; et des intermédiaires utiles dans cette fabrication.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)